Other · developed by Editas Medicine
EDIT-401 is a drug studied in heterozygous familial hypercholesterolemia (HeFH), a condition marked by high LDL cholesterol.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07894887 | Phase 1/2 | Heterozygous Familial Hypercholesterolemia (HeFH) | Not yet recruiting | EDIT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Heterozygous Familial Hypercholesterolemia (HeFH)
See EDIT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EDIT catalysts and pipeline →